Melanoma Research Victoria

Source: OncLive, May 2019 Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma. Patients with BRAF-mutant or BRAF wild-type melanoma who are eligible for immunotherapy can receive single-agent PD-1 inhibition or combination immunotherapy comprised of a PD-1 inhibitor and a […]

Read the full story

Source: Medscape, May 2019 This transcript has been edited for clarity. Hello. I am Dr Jeffrey Weber. I’m deputy director of and a medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health in New York City. Today I will be discussing a very interesting study that was recently reported in […]

Read the full story

Source: Modern Medicine Network, May 2019 Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.

Read the full story

Source: OncLive, May 2019 Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma. This biggest advancement in this treatment paradigm over the last several years has been the advent of combination therapies, Johnson says. […]

Read the full story